Technical Analysis for ORTX - Orchard Therapeutics plc

Grade Last Price % Change Price Change
grade C 15.49 -0.06% -0.01
ORTX closed down 0.06 percent on Tuesday, September 17, 2019, on 2.71 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Earnings due: Sep 27

*** please verify all earnings dates ***
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Down
See historical ORTX trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Crossed Above 200 DMA Bullish -0.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.06%
Inside Day Range Contraction -0.06%
Fell Below 200 DMA Bearish 3.06%
20 DMA Support Bullish 3.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.06%
200 DMA Support Bullish -1.09%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.09%
Calm After Storm Range Contraction -1.09%

Older signals for ORTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
ORTX Chart by TradingView
Basic chart:
Profile
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.
Biotechnology Health Biopharmaceutical Nature Therapy Hemoglobinopathies
Is ORTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 17 Guggenheim sees two-bagger in Orchard Therapeutics in premarket analyst action
Sep 13 Orchard Therapeutics commercial chief bids adieu
Sep 13 Orchard Therapeutics Announces Departure of Chief Commercial Officer
Sep 10 Orchard Therapeutics (ORTX) Presents At Morgan Stanley 17th Annual Global Healthcare Conference - Slideshow
Sep 5 Benzinga's Top Upgrades, Downgrades For September 5, 2019
Sep 5 Oppenheimer likes Incyte in premarket analyst action
Sep 4 Orchard Therapeutics Announces Encouraging Update from Proof-of-Concept Study of OTL-203 for the Treatment of Mucopolysaccharidosis Type I (MPS-I)
Sep 4 Orchard Therapeutics Presents an Integrated Data Analysis Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of Metachromatic Leukodystrophy
Sep 3 Orchard Therapeutics to Webcast Presentation at the Morgan Stanley 17th Annual Global Healthcare Conference
Sep 2 The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight
See more ORTX news...
Indicators
Indicator Value
52 Week High 21.64
52 Week Low 8.65
Average Volume 201,566
200-Day Moving Average 15.4828
50-Day Moving Average 14.0552
20-Day Moving Average 14.853
10-Day Moving Average 15.676
Average True Range 0.9229
ADX 16.13
+DI 28.4358
-DI 20.1634
Chandelier Exit (Long, 3 ATRs ) 14.7113
Chandelier Exit (Short, 3 ATRs ) 15.7587
Upper Bollinger Band 16.8515
Lower Bollinger Band 12.8545
Percent B (%b) 0.66
BandWidth 26.910388
MACD Line 0.5075
MACD Signal Line 0.4817
MACD Histogram 0.0257
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.44
Resistance 3 (R3) 17.65 17.21 17.12
Resistance 2 (R2) 17.21 16.71 17.11 17.01
Resistance 1 (R1) 16.35 16.41 16.13 16.14 16.90
Pivot Point 15.91 15.91 15.80 15.81 15.91
Support 1 (S1) 15.05 15.41 14.83 14.84 14.08
Support 2 (S2) 14.61 15.11 14.51 13.97
Support 3 (S3) 13.75 14.61 13.87
Support 4 (S4) 13.54